Specialty pharmaceutical company, Orient EuroPharma Co., Ltd. and Swiss-based global biopharmaceutical company, Debiopharm Group have signed a distribution agreement for the commercialization and promotion of Pamorelin in South East Asia.

Orient EuroPharma and Debiopharm also announced the launch of Pamorelin in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin will be made available primarily to urologists and oncologists across Singapore

JP Chang, president of pharmaceutical business unit, Orient EuroPharma said that “it is great to cooperate with Debiopharm Group for introducing the new drug to South East Asian territories. Orient EuroPharma owns strong connections and an experienced team in the Oncology field; this partnership will provide another therapy option for physicians to treat prostate cancer patients”.

“This collaboration opens up an important new market for our backbone therapy of advanced prostate cancer (locally advanced and metastatic)” said Thierry Mauvernay, Delegate of the Board, Debiopharm Group. “After successful launch in 74 countries, we look forward to bringing Pamorelin to several South East Asian markets, together with Orient EuroPharma”

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month formulations have already been registered in numerous countries and are available under different brand names: Trelstar, Decapeptyl and Pamorelin. The 6-month formulation has been registered and is available in Singapore, Europe and the US

Orient EuroPharma Co., Ltd. (OEP) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines, and a strong sales network of 360 dedicated and experienced sales representatives.

Debiopharm Group is a Swiss-based global biopharmaceutical group of 4 companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments.